
“I think it’s really important that people keep signing up to these type of trials to push research forward.”
Please note - this trial is no longer recruiting patients. We hope to add results when they are available.
This trial is looking at a new drug called linsitinib for Ewings sarcoma. It is for people whose Ewings sarcoma has continued to grow during treatment or has come back after treatment.
Doctors can treat Ewings sarcoma with chemotherapy, surgery and radiotherapy. Unfortunately for some people their sarcoma doesn’t respond to these treatments or it comes back after treatment. When this happens there are very few treatments available.
Researchers think that linsitinib may be able to help people whose Ewings sarcoma has not responded to treatment or has come back. Linsitinib is a biological therapy called a cancer growth blocker. It stops signals that cancer cells use to divide and grow.
The aims of this trial are to find out
You may be able to join this trial if you are going to the Churchill Hospital in Oxford and all of the following apply
You cannot join this trial if any of these apply. You
This is a phase 2 trial. The researchers need 40 people across Europe to join, including 10 people from the Churchill Hospital, Oxford in the UK.
Everyone taking part will have linsitinib. You take 4 linsitinib tablets once a day, before or after a meal. You take them for 3 days each week and then have 4 days of not taking them. You have a diary to record when you take the tablets.
After 3 weeks of treatment, you have a scan to see if it is helping. You can continue to have linsitinib as long as it is helping and the side effects aren’t too bad.
The researchers will ask for a sample of your sarcoma that was removed when you had surgery or a before starting treatment. They will ask for another sample of your sarcoma during treatment. They will also ask for some blood samples before starting treatment and a number of times during treatment. They will use these samples to find out what happens to linsitinib in the body.
You see the doctor to have some tests before taking part. These tests include
During treatment you see the doctor every 3 weeks for a physical examination, blood tests and heart trace. You have a PET-CT scan every 6 weeks.
You see the doctor at the end of treatment for the same tests you had at the start, apart from the heart scan.
After treatment your doctor will tell you how often they want to see you.
Linsitinib is a new drug and there may be side effects we don’t know about yet. The most common side effects reported so far include
Your doctor will talk to you about the possible side effects before you agree to take part in this trial.
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Andrew Bassim Hassan
Astellas
European Commission
NIHR Clinical Research Network: Cancer
University of Oxford
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040
“I think it’s really important that people keep signing up to these type of trials to push research forward.”